Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Keratitis - Overview
Keratitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Keratitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keratitis - Companies Involved in Therapeutics Development
Alfasigma SpA
AmebaGone Inc
Cumulus Pharmaceutical LLC
Dobecure SL
Editas Medicine Inc
Eleusis Ltd
EyeGate Pharmaceuticals Inc
Fox Chase Chemical Diversity Center Inc
iVee Delivery Systems Inc
MimeTech Srl
noViricides Inc
Oyster Point Pharma Inc
RegeneRx Biopharmaceuticals Inc
Riptide Bioscience Inc
Shanghai Bendao Gene Technology Co Ltd
Shenyang Sinqi Pharmaceutical Co Ltd
Shulov Innovative Science Ltd
Sinsa Labs Inc
TGV-Inhalonix Inc
Veloce BioPharma LLC
Viraze
Keratitis - Drug Profiles
acyclovir sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-2088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BD-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Bacterial Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELE-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ethamsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Herpetic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IVMED-90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDE-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KU-55933 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PIM-45 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-557 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Herpetic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit D Synthesis for Herpetic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
timbetasin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBP-245 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voricozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-9445 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Keratitis - Dormant Projects
Keratitis - Discontinued Products
Keratitis - Product Development Milestones
Featured News & Press Releases
May 14, 2020: ReGenTree announces efficacy results of the neurotrophic keratopathy phase 3 clinical trial with RGN-259
Apr 02, 2020: New provide pandemic response program to clients for T?4 in Corneal Wound Healing and Regeneration
Oct 23, 2019: Eleusis presents new research on the anti-inflammatory potential of serotonin 2A receptor agonists at the 2019 Intertiol Society for Research on Psychedelics
Dec 05, 2018: Recordati receives orphan drug desigtion for its investigatiol treatment for neurotrophic keratitis
Jun 01, 2016: RegeneRx and Lee’s Pharm Announce Acceleration of RGN-259 Development in Chi
Jan 12, 2016: noViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Keratitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Keratitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Keratitis - Pipeline by Alfasigma SpA, H2 2020
Keratitis - Pipeline by AmebaGone Inc, H2 2020
Keratitis - Pipeline by Cumulus Pharmaceutical LLC, H2 2020
Keratitis - Pipeline by Dobecure SL, H2 2020
Keratitis - Pipeline by Editas Medicine Inc, H2 2020
Keratitis - Pipeline by Eleusis Ltd, H2 2020
Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2020
Keratitis - Pipeline by Fox Chase Chemical Diversity Center Inc, H2 2020
Keratitis - Pipeline by iVeena Delivery Systems Inc, H2 2020
Keratitis - Pipeline by MimeTech Srl, H2 2020
Keratitis - Pipeline by NanoViricides Inc, H2 2020
Keratitis - Pipeline by Oyster Point Pharma Inc, H2 2020
Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2020
Keratitis - Pipeline by Riptide Bioscience Inc, H2 2020
Keratitis - Pipeline by Shanghai Bendao Gene Technology Co Ltd, H2 2020
Keratitis - Pipeline by Shenyang Sinqi Pharmaceutical Co Ltd, H2 2020
Keratitis - Pipeline by Shulov Innovative Science Ltd, H2 2020
Keratitis - Pipeline by Sinsa Labs Inc, H2 2020
Keratitis - Pipeline by TGV-Inhalonix Inc, H2 2020
Keratitis - Pipeline by Veloce BioPharma LLC, H2 2020
Keratitis - Pipeline by Viraze, H2 2020
Keratitis - Dormant Projects, H2 2020
Keratitis - Discontinued Products, H2 2020